Business
Supernus Announces First Quarter 2026 Financial Results
Total revenues were $207.7 million in the first quarter 2026, a 39% increase compared to same period last year.Combined revenues of the Company's four growth products increased to $149.1 million in the first quarter 2026, representing an increase of 56% compared to the same period last year. This strong growth was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™.Regulatory submission to the FDA for second supplier for ONAPGO expect
About this update from Supernus Pharmaceuticals, Inc.
ROCKVILLE, Md., May 05, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2026 and associated Company developments. “Our first quarter results reflect a strong start to the year, including a 56% year-over-year increase in combined revenues of our growth products,” said Jack Khattar, President and CEO of Supernus. “We have positive momentum across our business, and I look forward to continued strong growth and execution of our key products throughout the year.” Commercial Highlights Product Pipeline Update SPN-817 – Novel first-in-class highly selective AChE inhibitor for epilepsy SPN-820 – Novel first-in-class molecule that increases mTORC1 mediated synaptic function for depression SPN-443 – Novel stimulant for attention-deficit/hyperactivity disorder (ADHD) Financial Highlights This section includes information on non-GAAP financial measures. See "Non-GAAP Financial Information" section for information on non-GAAP financial measures. In addition, a reconciliation of applicable GAAP to non-GAAP financial information is included at the end of this press release. Revenues The following table provides information regarding total revenues (dollars in millions): Total revenues from commercial products (non-GAAP)(1)(4) represent revenues from our product sales to customers and through our collaboration agreement with Biogen. Other Financial Highlights Full Year 2026 Financial Guidance For the full year 2026, the Company reiterates its full year financial guidance as set forth below (dollars in millions): Non-GAAP Financial Information This press release contains financial measures that present financial information which do not comply with United States generally accepted accounting principles (GAAP). The non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, or superior to measures prepared in accordance with GAAP. Non-GAAP adjusted operating earnings on a historical and projected basis adjusts for non-cash share-based compensation expense, depreciation and amortization, intangible asset impairment charges and changes to fair value of contingent consideration, and for factors that a...
View stock analysis, news, and events for Supernus Pharmaceuticals, Inc.